Literature DB >> 17261078

Does human attractin have DP4 activity?

Daniel Friedrich1, Torsten Hoffmann, Joachim Bär, Michael Wermann, Susanne Manhart, Ulrich Heiser, Hans-Ulrich Demuth.   

Abstract

Mutations in the mouse ATRN gene, which encodes attractin, offer links between this protein and pigmentation, metabolism, immune status and neurodegeneration. However, the mechanisms of attractin action are not understood. The protein was first identified in humans in a circulating form in serum. A protease activity was postulated similar to the membrane-bound ectoenzyme DP4/CD26. In the last decade, both DP4/CD26 and attractin were controversially described to be the major source of human serum DP4 activity. We purified attractin from human plasma, and found that the DP4-like activity of the preparation shows nearly identical kinetic properties to that of recombinant human DP4. In contrast, the native electrophoretic behavior of this activity is clearly different from human and porcine DP4, but co-migrates with the protein band identified as attractin by Western blotting and N-terminal sequencing. Nevertheless, a DP4 impurity could be demonstrated in purified plasma attractin and the activity could be removed by ADA affinity chromatography, resulting in a homogenous attractin preparation without DP4 activity. These results are substantiated by expression of different attractin isoforms, in which no DP4 activity was found either. This indicates that the multidomain protein attractin acts as a receptor or adhesion protein rather than a protease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17261078     DOI: 10.1515/BC.2007.017

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  8 in total

Review 1.  Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.

Authors:  C Klemann; L Wagner; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-05-13       Impact factor: 4.330

2.  Potential of soluble CD26 as a serum marker for colorectal cancer detection.

Authors:  Oscar J Cordero; Monica Imbernon; Loretta De Chiara; Vicenta S Martinez-Zorzano; Daniel Ayude; Maria Paez de la Cadena; F Javier Rodriguez-Berrocal
Journal:  World J Clin Oncol       Date:  2011-06-10

Review 3.  Lymphocytes are a major source of circulating soluble dipeptidyl peptidase 4.

Authors:  A Casrouge; A V Sauer; R Barreira da Silva; M Tejera-Alhambra; S Sánchez-Ramón; C Cancrini; M A Ingersoll; A Aiuti; M L Albert
Journal:  Clin Exp Immunol       Date:  2018-09-24       Impact factor: 4.330

Review 4.  Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins.

Authors:  L Wagner; C Klemann; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-03-02       Impact factor: 4.330

5.  The role of dipeptidyl peptidase-IV in abdominal aortic aneurysm pathogenesis: A systematic review.

Authors:  Elisha Ngetich; Pierfrancesco Lapolla; Anirudh Chandrashekar; Ashok Handa; Regent Lee
Journal:  Vasc Med       Date:  2021-08-16       Impact factor: 3.239

6.  Dipeptidyl peptidase 4 inhibitor sitagliptin protected against dextran sulfate sodium-induced experimental colitis by potentiating the action of GLP-2.

Authors:  Meng-Meng Ning; Wen-Ji Yang; Wen-Bo Guan; Yi-Pei Gu; Ying Feng; Ying Leng
Journal:  Acta Pharmacol Sin       Date:  2020-05-12       Impact factor: 7.169

7.  Non-cell autonomous impairment of oligodendrocyte differentiation precedes CNS degeneration in the Zitter rat: implications of macrophage/microglial activation in the pathogenesis.

Authors:  Shin-ichi Sakakibara; Kazuhiko Nakadate; Shigeo Ookawara; Shuichi Ueda
Journal:  BMC Neurosci       Date:  2008-04-05       Impact factor: 3.288

8.  Evaluation of pleural effusion sCD26 and DPP-IV as diagnostic biomarkers in lung disease.

Authors:  Nuria Sánchez-Otero; Francisco Javier Rodríguez-Berrocal; María Páez de la Cadena; María Isabel Botana-Rial; Oscar J Cordero
Journal:  Sci Rep       Date:  2014-02-06       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.